Chen Ling
About Chen Ling
Chen Ling is the Director of Clinical Biomarker at BeiGene in Shanghai, China, with extensive experience in biomarker strategy development and implementation across multiple clinical trials.
Current Role
Chen Ling is currently the Director of Clinical Biomarker at BeiGene, based in Shanghai, China. The role involves leading the clinical biomarker strategy development and implementation for multi-regional clinical trials. This includes overseeing phase 1, 2, and 3 trials, supporting regulatory filings, and collaborating with diagnostic partners to develop and register companion diagnostics (CDx).
Professional Experience
Chen Ling has a substantial career history in the biopharmaceutical industry. Before joining BeiGene, Ling served as the Vice President of Preclinical Research at Zensun (Shanghai) Sci & Tech Co. from 2018 to 2019. Prior to that, he held various roles at Novartis Institutes for BioMedical Research (NIBR), including Investigator II from 2015 to 2018, and Investigator I from 2012 to 2015. Earlier experience includes positions at Roche, serving as Project Leader in 2012 and Senior Scientist from 2010 to 2011. Ling began his professional career as a Postdoctoral Fellow at The Johns Hopkins University School of Medicine from 2006 to 2010.
Educational Background
Chen Ling pursued his academic studies at several prestigious institutions. He obtained his Post-Doctoral Fellowship specializing in Signaling Pathways from The Johns Hopkins University School of Medicine, where he studied from 2006 to 2010. Ling earned his Ph.D. in Biochemistry and Molecular Biology from Shanghai Institutes of Biochemistry and Cell Biology, completing this program between 2001 and 2006. He also holds a Bachelor's degree in Biology from Fudan University, obtained after four years of study from 1997 to 2001.
Industry Contributions
Chen Ling has made significant contributions to the field of biomarkers and clinical trials. He has led the development and implementation of biomarker strategies for over 15 multi-regional clinical trials, including phases 1, 2, and 3. His efforts supported the supplemental Biologics License Application (sBLA) filing, which led to one NMPA approval and one initial submission. Ling has also presented biomarker data at notable conferences such as AACR, ASCO, and CSCO.
Expertise in Clinical Biomarkers
Chen Ling possesses deep expertise in biomarker assay setup, outsourcing, and monitoring. His role requires effective collaboration with internal and external stakeholders to ensure successful biomarker initiatives. Ling has worked closely with diagnostic partners to develop and register companion diagnostics (CDx), showcasing his proficiency in integrating clinical biomarkers into broader therapeutic contexts.